A Phase II Study of Serplulimab Plus Chemoradiotherapy as Adjuvant Treatment for Postoperative Cervical Cancer with Multiple Risk Factors
Voluntarily participate in the clinical study: Fully understand and be informed about the study, and sign the informed consent form (ICF); willing to comply with and capable of completing all trial procedures.
Female aged ≥18 years and ≤65 years at the time of signing the ICF.
ECOG PS score of 0 or 1.
Positive PD-L1 status (CPS ≥1).
Patients with unresectable residual tumors.
Histologically confirmed diagnosis of cervical small cell carcinoma (neuroendocrine) or mucinous adenocarcinoma.
Patients who have previously received pelvic radiotherapy.
History of other untreated malignant tumors within the past 5 years, except for cured basal cell carcinoma of the skin or carcinoma in situ.